Holen Sie sich die Stockscreener-App
1.815
15.41%
0.225
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt CTXR?
Forum
Prognose
Aktiensplit
Schlusskurs vom Vortag:
$1.59
Offen:
$1.62
24-Stunden-Volumen:
1.49M
Relative Volume:
0.75
Marktkapitalisierung:
$10.94M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-39.14M
KGV:
-0.304
EPS:
-5.97
Netto-Cashflow:
$-28.20M
1W Leistung:
+42.25%
1M Leistung:
+169.85%
6M Leistung:
-54.12%
1J Leistung:
-86.49%
1-Tages-Spanne:
$1.60
$1.90
1-Wochen-Bereich:
$1.16
$1.90
52-Wochen-Spanne:
$0.65
$26.25
Citius Pharmaceuticals Inc Stock (CTXR) Company Profile
Firmenname
Citius Pharmaceuticals Inc
Sektor
Branche
Telefon
(908) 967-6676
Adresse
11 COMMERCE DRIVE, CRANFORD, NJ
Vergleichen Sie CTXR mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
CTXR
Citius Pharmaceuticals Inc
|
1.835 | 10.94M | 0 | -39.14M | -28.20M | -5.97 |
|
VRTX
Vertex Pharmaceuticals Inc
|
452.23 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
539.99 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
324.87 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
549.52 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
243.88 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Citius Pharmaceuticals Inc Stock (CTXR) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-12-30 | Hochstufung | D. Boral Capital | Hold → Buy |
| 2021-11-30 | Eingeleitet | Maxim Group | Buy |
Citius Pharmaceuticals Inc Aktie (CTXR) Neueste Nachrichten
Citius Oncology prepares for lymphoma treatment launch in 2025 By Investing.com - Investing.com Nigeria
Citius Oncology On Track to Launch Lymphir in US in H2 - MarketScreener
Citius Oncology prepares for lymphoma treatment launch in 2025 - Investing.com
Citius Oncology Anticipates Commercial Launch of LYMPHIR™ in 2025 - PR Newswire
Millennium Management LLC Sells 1,126,188 Shares of Citius Pharmaceuticals, Inc. (NASDAQ:CTXR) - Defense World
Citius Oncology enters distribution services agreement with Cardinal Health - MSN
Citius Pharmaceuticals Announces Closing of Registered Direct Offering of Up To $15.8 Million Priced At-The-Market Under Nasdaq Rules - The Victoria Advocate
Citius Pharmaceuticals Closes $6M Securities Offering - TipRanks
After Major Oncology Conference, All Eyes Turn to Industry Innovation - Quantisnow
Citius Pharmaceuticals Announces Closing Of Registered Direct Offering Of Up To $15.8 Million Priced At-The-Market Under Nasdaq Rules - MarketScreener
Citius Pharmaceuticals Announces Closing of Registered Direct Offering of Up To $15.8 Million Priced At-The-Market Under Nasdaq Rules | CTXR Stock News - GuruFocus
Citius Pharmaceuticals Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits - Quantisnow
Citius Pharmaceuticals Secures $15.8M Financing Deal: What This Means for LYMPHIR Commercialization - Stock Titan
Citius Pharmaceuticals Announces a Registered Direct Offering of Up To $15.8 Million Priced At-The-Market Under Nasdaq Rules - Longview News-Journal
Citius Pharmaceuticals (CTXR) Target Price Reduced Amid Fundrais - GuruFocus
Citius Pharma secures $6 million in stock offering By Investing.com - Investing.com South Africa
Citius Pharmaceuticals (CTXR) Target Price Reduced Amid Fundraising Efforts | CTXR Stock News - GuruFocus
Citius Pharmaceuticals Stock Is Falling Tuesday: What's Going On? - Benzinga
Citius Pharmaceuticals (CTXR) Announces $6 Million Direct Offeri - GuruFocus
Citius Pharmaceuticals (CTXR) Announces $6 Million Direct Offering - GuruFocus
Citius Pharmaceuticals (CTXR) Price Target Lowered, Rating Maint - GuruFocus
Citius Pharmaceuticals announces registered direct offering of $15.8 million - MSN
Citius Pharma secures $6 million in stock offering - Investing.com Australia
Citius Pharmaceuticals (CTXR) Announces Stock and Warrant Offeri - GuruFocus
Citius Pharmaceuticals (CTXR) Announces Stock and Warrant Offering | CTXR Stock News - GuruFocus
Citius Pharma Announces Direct Offering - Nasdaq
Citius Pharmaceuticals Announces a Registered Direct Offering of - GuruFocus
Citius Pharmaceuticals (NASDAQ:CTXR) Given “Buy” Rating at D. Boral Capital - Defense World
Citius Pharmaceuticals expands authorized shares By Investing.com - Investing.com Nigeria
Citius Oncology partners with Cardinal Health for LYMPHIR distribution By Investing.com - Investing.com South Africa
Citius Pharmaceuticals (CTXR) Receives Continued Buy Rating from Analyst | CTXR Stock News - GuruFocus
Citius Pharmaceuticals expands authorized shares - Investing.com
Citius Pharmaceuticals Stock Is Soaring Monday: What's Going On? - Benzinga
Citius Oncology Signs US Distribution Deal With Cardinal Health for Lymphir - marketscreener.com
Cardinal Health (CAH) Partners with Citius Oncology for LYMPHIR Distribution | CAH Stock News - GuruFocus
Citius Oncology Inks Distribution Services Agreement With Cardinal Health For LYMPHIR - Nasdaq
Citius Oncology stock soars on distribution deal By Investing.com - Investing.com South Africa
Citius Oncology stock soars on distribution deal - Investing.com Australia
Citius Oncology partners with Cardinal Health for LYMPHIR distribution - Investing.com
Citius Oncology Enters into Distribution Services Agreement with Cardinal Health | CTXR Stock News - GuruFocus
Citius Oncology Enters into Distribution Services Agreement with Cardinal Health - Yahoo Finance
Squarepoint Ops LLC Sells 609,711 Shares of Citius Pharmaceuticals, Inc. (NASDAQ:CTXR) - Defense World
Northern Trust Corp Sells 306,583 Shares of Citius Pharmaceuticals, Inc. (NASDAQ:CTXR) - Defense World
Citius Pharmaceuticals, Inc. Reports Fiscal Second Quarter 2025 Financial Results and Provides Business Update - mx.advfn.com
Citius Pharmaceuticals Issues $1M Promissory Note to Pagoda - TipRanks
Citius Pharmaceuticals, Inc. (NASDAQ:CTXR) Receives $54.50 Consensus Price Target from Brokerages - Defense World
Why Shares of SoundHound AI Are Soaring Today - The Globe and Mail
Citius Pharmaceuticals (NASDAQ:CTXR) Cut to Hold at Maxim Group - Defense World
Maxim Group Downgrades Citius Pharmaceuticals (CTXR) - MSN
This Deckers Outdoor Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Friday - Benzinga
Citius Pharmaceuticals (CTXR) Downgraded to Hold by Maxim Group - GuruFocus
Finanzdaten der Citius Pharmaceuticals Inc-Aktie (CTXR)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.70%
0.53%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):